NeuBase Therapeutics
700 Technology Drive
Pittsburgh
PA
15219
United States
Website: https://www.neubasetherapeutics.com/
47 articles about NeuBase Therapeutics
-
NeuBase to Participate in Jefferies 2023 Healthcare Conference
5/24/2023
NeuBase Therapeutics, Inc. announced that the Company’s management will participate in the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on June 7-9, 2023.
-
NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™
5/22/2023
NeuBase Therapeutics, Inc. today announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program that demonstrate the ability to achieve gene editing with a non-immunogenic system.
-
NeuBase Announces Formation of Gene Editing Advisory Board
5/16/2023
NeuBase Therapeutics, Inc. announced the formation of a gene editing advisory board comprised of distinguished leaders of the scientific community who will support the development of the differentiated gene editing capabilities of the Company’s PATrOL™ platform.
-
NeuBase Reports Business Update and Financial Results for the First Quarter of 2023
5/11/2023
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today reported its financial results for the three-month period ended March 31, 2023 and other recent developments.
-
NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
5/2/2023
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting.
-
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023
2/14/2023
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended December 31, 2022, and other recent developments.
-
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022
12/21/2022
NeuBase Therapeutics, Inc. today reported its financial results for the fiscal year ended September 30, 2022, and other recent developments.
-
Huntington’s disease might just top the list of intractable neurodegenerative diseases. BioSpace spoke with the field's foremost experts about the challenges and how to overcome them.
-
NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company
10/21/2022
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced a research agreement with a Top 10 Global Healthcare company (“Healthcare Company”) (based on 2021 revenues).
-
NeuBase announced a strategic restructuring, diverting resources from its Huntington's program and shedding 60% of its workforce.
-
NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing
10/14/2022
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today announced plans to restructure the Company to focus on the advancement of its platform in gene editing. Implementation of this strategy, which follows a strategic internal review by the Company’s board of directors and management team.
-
NeuBase to Participate at Chardan’s 6th Annual Genetic Medicines Conference
9/22/2022
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced that company management will participate in-person for a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference being held in New York City on October 3-4, 2022.
-
NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
8/11/2022
NeuBase Therapeutics, Inc. today reported its financial results for the three-month period ended June 30, 2022, and other recent developments.
-
NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO
6/29/2022
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced the promotion of William (Bill) Mann, Ph.D. to President of the Company, effective immediately.
-
NeuBase to Participate at the Jefferies Healthcare Conference - June 01, 2022
6/1/2022
NeuBase Therapeutics, Inc. announced that company management will present a corporate overview at the Jefferies Healthcare Conference being held in New York on June 8 – 10, 2022.
-
NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution
5/17/2022
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced the presentation of preclinical pharmacokinetics (PK) and biodistribution data for its lead development candidate, NT-0231.
-
The ASGCT's 25th Annual Meeting features the latest scientific research in genetics and cellular therapies. Read on for highlights from the meeting.
-
NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022
5/12/2022
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended March 31, 2022, and other recent developments.
-
NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
5/2/2022
NeuBase Therapeutics, Inc. announced two abstracts have been accepted for presentation at the American Society of Gene and Cell Therapy 25th Annual Meeting, taking place virtually and in person in Washington, D.C., May 16-19, 2022.
-
NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal
3/13/2022
NeuBase Therapeutics, Inc., a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced new preclinical data for its lead development candidate, NT-0231.F, to treat myotonic dystrophy type 1.